An outbreak of the coronavirus disease (COVID-19), resulting from a respiratory infection of SARS-CoV-2, has continued to spread throughout the world and become a global health emergency. COVID-19 activates the inflammatory response of the immune system resulting in serious pathologies. Consequently, PubMed, Scopus and google scholar databases were examined up to April 2021, using suitable keywords to understand the effect of COVID-19 on the different disease states of the immune system.  Individual and pooled prevalence rates with 95% confidence intervals (CI) will be calculated using the fixed- or random-effects model as appropriate. Identification of the independent parameters based on age, sex, and illness to understand the effect of COVID-19 and will be carried out using the fixed and random-effects meta-analysis models as appropriate. Male patients and older individuals have been shown to have worse disease outcomes due to poor T-cell activation by the immune system, compared to the female sex or younger individuals. The effects of COVID-19 on the immune system and existing immunological disorders have yet to be fully discussed. The mortality rate of COVID-19 is estimated to be between 1 and 5%, but this may be higher in individuals with immune-deficiency conditions. In common immune disorders, such as rheumatoid arthritis and type 1 diabetes mellitus, the severity of symptoms and mortality rate are increased. In the case of type-1 diabetes mellitus, there was found to be an associated two-fold increase in mortality and severity of COVID-19 in patients with diabetes mellitus compared to individuals without diabetes. Individuals with Systemic Lupus Erythematous experience hypomethylation and overexpression of the ACE2 protein, which may explain the possible increased viral entry, viremia, and excessive immune response to COVID-19. This analysis will establish the impact of COVID-19 on immunological disorders and how this compares to other viral infections.